The Tesla stock price today climbed over 4% after an impressive amount of people pre-ordered the Model 3.
The Model 3 has a price tag of $35,000, and there are already 276,000 people who have reserved the vehicle.
Category
Stocks to Watch
One $9 Stock That Gets You into a $75 Billion Growth Market
China is pushing its automakers to meet improved fuel standards.
Thanks to the government's mandate, China stands at the center of a technological breakthrough that'll roil this $75 billion slice of the automotive market.
Here's what you need to know...
Profit from 2016 IPOs with These Two "Icebreakers"
Yes, there's been a low volume of 2016 IPOs due to broader market volatility.
But the IPO market is about to stage a massive turnaround.
And this chart examines why the 2016 IPO market is ready to bounce back...
How to Protect Your Biotech Profits from This Legal Limbo
Gilead Sciences Inc.'s Sovaldi was a real breakthrough in the fight against the chronic liver disease hepatitis C (HCV). The condition may show no symptoms for years after initial infection but can slowly become debilitating.
Hepatitis C affects as many as 200 million people worldwide, and before Sovaldi, the approved drug regimen could treat only about 50% of cases and could cause serious side effects. Treatment was generally long – 24 to 48 weeks – and arduous.
Sovaldi, on the other hand, could cure more than 90% of cases in a matter of weeks at a cost, in the United States, of around $94,000. The pricing caused controversy, but the drug proved transformative for HCV patients, their families, and doctors.
Sovaldi also proved a huge windfall for investors when it received FDA approval in 2013 and entered the pharmaceutical marketplace the following year.
So far, Gilead shareholders have seen a 2:1 split, several dividend payouts, and gains of more than 155% since 2013. Sales of Sovaldi and Gilead's other HCV drug, Harvoni, topped $12.5 billion in 2015 alone.
There's just one big, expensive problem...
Why the SUNE Stock Price Dropped to a 20-Year Low Today
Things just keep getting worse for SunEdison as the SUNE stock price has crashed another 44% today (Tuesday) to $0.70 per share. The SUNE stock price is now down more than 64% in the last month.
This is the first time the SunEdison Inc. (NYSE: SUNE) stock price has traded below $1 since 1995. The future for the company looks bleaks, with a bankruptcy filing looking likely.
Here's why the SUNE stock price is crashing today...
3 Reasons the Price of Silver Will Rebound from Recent Lows
The price of silver has been on a tear, but that has halted – temporarily.
To find out what's next for silver, we are looking at some indicators that give clues to where the white metal is headed.
And what these signs show us is silver-price strength ahead...
Why the Bull Run for Gold Prices Will Continue in 2016
After a relentless rise from their December depths, gold prices now appear to be taking a break.
Does that mean gold's renewed bull is over? Or is this just a temporary reprieve before the gold price reverses and heads higher?
Let's take a closer look at this past week's movement...
GOOGL Stock Benefiting from $200 Billion Cloud-Computing War
The GOOGL stock price is up over 33% in the last 12 months, but the company is lagging behind in the cloud-computing war.
In fact, the tech giant only has 4% of the market.
Who Are the Top CEOs in the $150 Billion Virtual Reality Market?
Two of the top CEOs in tech were just placed on Barron's List of Top 30 CEOs for 2016.
We think they made two wise choices, and long-term investors are going to be rewarded by these visionaries.
Why AAPL Stock Is a Buy After "Snoozer" Event
AAPL stock has reacted to Monday's Apple Event news pretty much like the tech media did – with a big yawn.
But most people have completely missed the significance of what Apple is doing.
That reading of the debut of the iPhone 5SE greatly underestimates Apple's plans. It's part of a grand strategy that will boost earnings m